| Names | |
|---|---|
|
Preferred IUPAC name
(2E)-3-(1H-imidazol-4-yl)prop-2-enoic acid
|
|
| Other names
(E)-3-(1H-imidazol-4-yl)acrylic acid
|
|
| Identifiers | |
|
104-98-3 |
|
| 3D model (Jmol) | Interactive image |
| ChEBI |
CHEBI:30817 |
| ChemSpider |
643824 |
| ECHA InfoCard | 100.002.963 |
| MeSH | Urocanic+acid |
| PubChem | 1178 |
|
|
|
|
| Properties | |
| C6H6N2O2 | |
| Molar mass | 138.124 g/mol |
| Melting point | 225 °C (437 °F; 498 K) |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
|
|
|
| Infobox references | |
Urocanic acid is an intermediate in the catabolism of L-histidine.
It is formed from L-histidine through the action of histidine ammonialyase (also known as histidase or histidinase) by elimination of ammonium.
In the liver, urocanic acid is transformed by urocanate hydratase (or urocanase) to 4-imidazolone-5-propionic acid and subsequently to glutamic acid.
Inherited deficiency of urocanase leads to elevated levels of urocanic acid in the urine, a condition known as urocanic aciduria.
Urocanic acid was detected in animal sweat and skin where, among other possible functions, it acts as an endogenous sunscreen or photoprotectant against UVB-induced DNA damage. Urocanic acid is found predominantly in the stratum corneum of the skin and it is likely that most of it is derived from filaggrin catabolism (a histidine-rich protein). When exposed to UVB irradiation, trans-urocanic acid is converted in vitro and in vivo to the cis isomer. The cis form is known to activate regulatory T cells.
Urocanic acid was first isolated in 1874 by the chemist Max Jaffé from the urine of a dog, hence the name (Latin: urina = urine, and canis = dog).